The ubiquitin proteasome system (UPS) is one of the most essential regulatory mechanisms within human cells. It controls protein quality, quantity, and turnover by identifying damaged or unnecessary proteins and directing them for degradation. This tightly regulated process is vital for maintaining cellular balance, also known as proteostasis.

Proteins are tagged with a small molecule called ubiquitin through a sequence of enzymatic steps. Once tagged, these proteins are delivered to the proteasome, a large protein complex that breaks them down into reusable components. This process ensures that cells can rapidly adapt to internal and external changes.

Disruption of the ubiquitin proteasome system can lead to severe consequences. Abnormal protein accumulation is linked to cancer, neurodegenerative disorders, immune dysfunction, and inflammatory diseases. Because of this central role, drugs that modulate proteasome activity have gained significant attention in modern medicine.

Ubiquitin proteasome–targeting drugs work by altering protein degradation pathways. Instead of allowing harmful proteins to persist, these drugs selectively interfere with proteasome function, triggering cell death in diseased cells while sparing normal ones. This approach has been particularly impactful in oncology.

By targeting a core cellular process, ubiquitin proteasome drugs represent a powerful therapeutic strategy rooted in fundamental biology rather than surface-level symptoms.